Thanks to LAISOLID, ROVI is advancing in the development of long-acting injectable formulations capable of preserving the stability and efficacy of complex active ingredients. This type of medication can reduce the frequency of administration, promoting greater patient comfort and better adherence to treatments.
The project is part of a broader strategy aimed at strengthening research and production capacity within the European pharmaceutical sector. With this initiative, ROVI consolidates its participation in large-scale projects focused on developing therapeutic solutions with potentially significant impact on clinical practice.
